Global lymphoma market is expected to grow at a significant rate over the forecast period. Rising prevalence of various types of lymphoma and high amount of R&D for development of novel drugs are the major factors driving the growth. In addition, other factors such as a rise in healthcare expenditure levels, established healthcare infrastructure, increase in health conscious population and rising government awareness programs are estimated to boost the market growth in coming six years.
Rising prevalence of lymphoma is considered as the highest rendering factor pertaining to market growth. According to the data published by the American Cancer Society, 79990 new cases of lymphomas were diagnosed in 2014 and around 20170 people are expected to die from this disease till 2016.
Another factor boosting the market growth is extensive R&D initiatives undertaken by pharmaceutical companies, academic and healthcare institutions for development of better and efficient diagnostic and therapeutic products. The launch of promising drugs such as next generation monoclonal antibodies, novel small molecule inhibitors and continuous use of current blockbuster drugs such as rituxan or mebthera are expected to be the key drivers for the market growth.
To request a sample copy or view summary of this report, click the link below:
http://www.grandviewresearch.com/industry-analysis/lymphoma-market
Swelling of lymph nodes, weight loss, fever, anorexia, dyspnea, itching fatigue and night sweats are the common symptoms of lymphoma. It generally occurs in lymph nodes, spleen, bone marrow, blood and other body organs. On the basis of type, the market is segmented into Hodgkin and non-Hodgkin lymphoma. The Hodgkin lymphoma is considered to be the most curable form of between the both. The average treatment span for patients is approximated to be five years. The most common type is non-Hodgkin which develops in lymph nodes and related tissues of the lymphatic system. According to the National Cancer Institute, it has been reported that non-Hodgkin accounts for 4.3% of all cancer cases in the U.S. Also it has been estimated that 71850 patients were suffering from non-Hodgkin disease and 19790 people have died due to this disease while 9050 new cases of Hodgkin lymphoma were diagnosed in the year 2015.
The diagnosis of this disease includes Fluorescence In Situ Hybridization testing (FISH), immunophenotyping and, flow cytometry. The therapeutic treatment for this disease includes chemotherapy, radiation therapy and, monoclonal antibody therapy. Among these treatments, a most widely used method is chemotherapy. It is estimated that around 20% to 30% of lymphoma patients undergo chemotherapy.
Various drugs involved in the treatment of this disease include Arranon (nelarabine), Adcertis (brentuximab), Decadron (dexamethasone), Adriamycin (doxorubicin), Deltasone (prednisone), Baycadron (dexamethasone), Folotyn (pralatrexate), and Roferon-A (interferon alfa-2a).
The strong product pipeline in this field is also expected to fuel the growth of this market over the decade. The robust pipeline of antibody-based therapies is designed to fulfil the unmet needs of the people. It includes Brentuximab Vedotin (ALCANZA) which targets cutaneous T-cell lymphoma, ECHELON-1 which targets mature T-cell lymphoma, and REVLIMID (lenalidomide) which targets follicular lymphoma and diffused large B-cell. These drugs are in Phase III of clinical trials and are expected to be launched over the forecast period. There are around 521 lymphoma drugs in development, out of which 33 are in Phase III, 168 in Phase II, 201 in Phase I, and others are in Preclinical stage.
On the basis of region, the market is segmented into North America, Europe, Asia-Pacific, Latin America and MEA. North America is estimated to hold the largest market share followed by Europe owing to the presence of a large number of key players involved in development and manufacturing of potential drugs. In addition, favorable government funding is also contributing towards high revenue share.
Asia Pacific region is expected to witness the fastest growth over the decade owing to rising incidences of lymphoma, growing patient awareness levels and its treatment, and increasing population base. In emerging countries such as India and China, increasing disposable income level, improving healthcare infrastructure and growing number of drug manufacturing companies is anticipated to further accentuate the market growth in this region.
About Grand View Research:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: www.grandviewresearch.com
Rising prevalence of lymphoma is considered as the highest rendering factor pertaining to market growth. According to the data published by the American Cancer Society, 79990 new cases of lymphomas were diagnosed in 2014 and around 20170 people are expected to die from this disease till 2016.
Another factor boosting the market growth is extensive R&D initiatives undertaken by pharmaceutical companies, academic and healthcare institutions for development of better and efficient diagnostic and therapeutic products. The launch of promising drugs such as next generation monoclonal antibodies, novel small molecule inhibitors and continuous use of current blockbuster drugs such as rituxan or mebthera are expected to be the key drivers for the market growth.
To request a sample copy or view summary of this report, click the link below:
http://www.grandviewresearch.com/industry-analysis/lymphoma-market
Swelling of lymph nodes, weight loss, fever, anorexia, dyspnea, itching fatigue and night sweats are the common symptoms of lymphoma. It generally occurs in lymph nodes, spleen, bone marrow, blood and other body organs. On the basis of type, the market is segmented into Hodgkin and non-Hodgkin lymphoma. The Hodgkin lymphoma is considered to be the most curable form of between the both. The average treatment span for patients is approximated to be five years. The most common type is non-Hodgkin which develops in lymph nodes and related tissues of the lymphatic system. According to the National Cancer Institute, it has been reported that non-Hodgkin accounts for 4.3% of all cancer cases in the U.S. Also it has been estimated that 71850 patients were suffering from non-Hodgkin disease and 19790 people have died due to this disease while 9050 new cases of Hodgkin lymphoma were diagnosed in the year 2015.
The diagnosis of this disease includes Fluorescence In Situ Hybridization testing (FISH), immunophenotyping and, flow cytometry. The therapeutic treatment for this disease includes chemotherapy, radiation therapy and, monoclonal antibody therapy. Among these treatments, a most widely used method is chemotherapy. It is estimated that around 20% to 30% of lymphoma patients undergo chemotherapy.
Various drugs involved in the treatment of this disease include Arranon (nelarabine), Adcertis (brentuximab), Decadron (dexamethasone), Adriamycin (doxorubicin), Deltasone (prednisone), Baycadron (dexamethasone), Folotyn (pralatrexate), and Roferon-A (interferon alfa-2a).
The strong product pipeline in this field is also expected to fuel the growth of this market over the decade. The robust pipeline of antibody-based therapies is designed to fulfil the unmet needs of the people. It includes Brentuximab Vedotin (ALCANZA) which targets cutaneous T-cell lymphoma, ECHELON-1 which targets mature T-cell lymphoma, and REVLIMID (lenalidomide) which targets follicular lymphoma and diffused large B-cell. These drugs are in Phase III of clinical trials and are expected to be launched over the forecast period. There are around 521 lymphoma drugs in development, out of which 33 are in Phase III, 168 in Phase II, 201 in Phase I, and others are in Preclinical stage.
On the basis of region, the market is segmented into North America, Europe, Asia-Pacific, Latin America and MEA. North America is estimated to hold the largest market share followed by Europe owing to the presence of a large number of key players involved in development and manufacturing of potential drugs. In addition, favorable government funding is also contributing towards high revenue share.
Asia Pacific region is expected to witness the fastest growth over the decade owing to rising incidences of lymphoma, growing patient awareness levels and its treatment, and increasing population base. In emerging countries such as India and China, increasing disposable income level, improving healthcare infrastructure and growing number of drug manufacturing companies is anticipated to further accentuate the market growth in this region.
About Grand View Research:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: www.grandviewresearch.com
No comments:
Post a Comment